HC Wainwright Reaffirms “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 147.22% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Royal Bank Of Canada began coverage on shares of Telix Pharmaceuticals in a report on Monday, December 15th. They issued a “hold” rating on the stock. UBS Group cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 23rd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Trading Up 0.5%

Shares of TLX opened at $8.09 on Monday. The stock has a 50 day simple moving average of $9.72 and a 200 day simple moving average of $11.71. Telix Pharmaceuticals has a 52-week low of $7.72 and a 52-week high of $30.36.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently bought and sold shares of TLX. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares during the last quarter. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $213,000. Blair William & Co. IL bought a new position in Telix Pharmaceuticals during the second quarter worth $217,000. JPMorgan Chase & Co. acquired a new position in shares of Telix Pharmaceuticals in the third quarter valued at $243,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at $297,000.

Trending Headlines about Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating with a $20 price target, a bullish analyst view that signals upside potential if Telix can resolve regulatory/legal issues and re‑accelerate product progress. Benzinga
• Negative Sentiment: Multiple plaintiff and shareholder‑rights law firms are urging Telix investors to act by Jan. 9, 2026 in a newly filed securities class action covering Feb 21–Aug 28, 2025 — publicity increases litigation risk, potential damages exposure, and ongoing legal costs. Representative notices: Levi & Korsinsky. Levi & Korsinsky, The Law Offices of Frank R. Cruz. Frank R. Cruz
• Negative Sentiment: Additional firms are circulating similar notices (Hagens Berman, Berger Montague, Gross Law, Faruqi & Faruqi, Portnoy, Bronstein)—the volume of notices amplifies investor attention and could pressure sentiment until regulatory and legal clarity arrives. Representative notices: Hagens Berman (calls out SEC subpoena & FDA CRL tied to CMC/supply chain), Berger Montague. Hagens Berman 21% plunge / SEC subpoena & FDA CRL Berger Montague

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.